Robert Young's Insider Trades & SAST Disclosures
Robert Young's most recent trade in 4D Molecular Therapeutics Inc was a trade of 92,300 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 6, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Robert Young.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| 4D Molecular Therapeutics Inc | Robert Young Kim | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2025 | 92,300 | 92,300 | - | - | Stock Option (Right to Buy) | |
| CBRE Group Inc - Ordinary ... | Robert M. Croft Young | Chief Investment Officer | 01 Aug 2024 | 1,041 | 16,827 (0%) | 0% | 112.4 | 116,998 | Class A Common Stock | |
| Nuveen Municipal Credit In... | Young L. Robert | Trustee | Purchase of securities on an exchange or from another person at price $ 12.40 per share. | 02 Jul 2024 | 16,131 | 16,131 (0%) | 0% | 12.4 | 200,024 | Common Stock |
| 4D Molecular Therapeutics Inc | Young Kim Robert | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2024 | 12,000 | 138,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Young Robert Kim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.66 per share. | 05 Feb 2024 | 12,000 | 13,595 | - | 18.7 | 223,920 | Common Stock |
| 4D Molecular Therapeutics Inc | Young Robert Kim | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 05 Feb 2024 | 12,000 | 1,595 | - | 30.1 | 360,600 | Common Stock |
| 4D Molecular Therapeutics Inc | Young Robert Kim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.78 per share. | 05 Feb 2024 | 6,000 | 7,595 | - | 15.8 | 94,680 | Common Stock |
| 4D Molecular Therapeutics Inc | Kim Young Robert | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.04 per share. | 05 Feb 2024 | 6,000 | 7,595 | - | 8.0 | 48,240 | Common Stock |
| 4D Molecular Therapeutics Inc | Kim Young Robert | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2024 | 6,000 | 64,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Young Robert Kim | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Feb 2024 | 6,000 | 54,000 | - | - | Stock Option (Right to Buy) | |
| 4D Molecular Therapeutics Inc | Kim Young Robert | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 05 Feb 2024 | 6,000 | 1,595 | - | 30.1 | 180,300 | Common Stock |
| 4D Molecular Therapeutics Inc | Robert Kim Young | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 05 Feb 2024 | 6,000 | 1,595 | - | 30.1 | 180,300 | Common Stock |
| 4D Molecular Therapeutics Inc | Kim Young Robert | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.05 per share. | 05 Feb 2024 | 552 | 1,043 | - | 30.1 | 16,588 | Common Stock |
| 4D Molecular Therapeutics Inc | Young Robert Kim | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2023 | 250,000 | 250,000 | - | - | Stock Option (Right to Buy) | |
| Nuveen Municipal Credit In... | Young L. Robert | Trustee | Sale of securities on an exchange or to another person at price $ 11.18 per share. | 17 Nov 2023 | 14,999 | 0 (0%) | 0% | 11.2 | 167,689 | Common Stock |
| Wesbanco, Inc. | Robert H. Young | Sr. EVP/CFO - Retired 12/31/21 | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2022 | 2,000 | 0 | - | - | Stock Option | |
| Wesbanco, Inc. | Robert H. Young | Sr. EVP/CFO - Retired 12/31/21 | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.58 per share. | 25 May 2022 | 2,000 | 25,698 (0%) | 0% | 31.6 | 63,160 | Common Stock |
| Wesbanco, Inc. | Robert H. Young | Sr. EVP/CFO - Retired 12/31/21 | Sale of securities on an exchange or to another person at price $ 32.80 per share. | 25 May 2022 | 2,000 | 23,698 (0%) | 0% | 32.8 | 65,600 | Common Stock |
| Wesbanco, Inc. | Robert H. Young | Sr. EVP/CFO - Retired 12/31/21 | Payment of exercise price or tax liability using portion of securities received from the company at price $ 31.67 per share. | 18 May 2022 | 1,816 | 21,882 (0%) | 0% | 31.7 | 57,513 | Common Stock |
| Wesbanco, Inc. | Robert H. Young | Sr. EVP/CFO - Retired 12/31/21 | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 May 2022 | 514 | 23,698 (0%) | 0% | 0 | Common Stock | |
| Wesbanco, Inc. | Robert H. Young | Sr. EVP/CFO - Retired 12/31/21 | Sale of securities on an exchange or to another person at price $ 36.00 per share. | 02 Feb 2022 | 7,211 | 23,184 (0%) | 0% | 36 | 259,596 | Common Stock |
| Wesbanco, Inc. | Robert H. Young | Sr. EVP/CFO - Retired 12/31/21 | Sale of securities on an exchange or to another person at price $ 36.03 per share. | 02 Feb 2022 | 7,000 | 30,395 (0%) | 0% | 36.0 | 252,210 | Common Stock |
| Team, Inc. | Robert Young | President, AID | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Nov 2021 | 12,308 | 12,308 | - | - | Restricted Stock Units | |
| Team, Inc. | Robert Young | President, AID | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 1,455 | 4,315 | - | - | Restricted Stock Units | |
| Team, Inc. | Robert Young | President, AID | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 1,455 | 10,554 (0%) | 0% | 0 | Common Stock | |
| Team, Inc. | Robert Young | President, AID | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 849 | 9,099 (0%) | 0% | 0 | Common Stock | |
| Team, Inc. | Robert Young | President, AID | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 849 | 2,520 | - | - | Restricted Stock Units | |
| Team, Inc. | Robert Young | President, AID | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 787 | 8,250 (0%) | 0% | 0 | Common Stock | |
| Team, Inc. | Robert Young | President, AID | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 787 | 1,295 | - | - | Restricted Stock Units | |
| Team, Inc. | Robert Young | President, AID | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 15 Nov 2021 | 469 | 3,846 | - | - | Restricted Stock Units | |
| Team, Inc. | Robert Young | President, AID | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 15 Nov 2021 | 274 | 2,246 | - | - | Restricted Stock Units | |
| Team, Inc. | Robert Young | President, AID | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 15 Nov 2021 | 254 | 1,041 | - | - | Restricted Stock Units | |
| Wesbanco, Inc. | Robert H. Young | Sr. EVP / CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 5,816 | 36,674 (0%) | 0% | 0 | Common Stock | |
| Wesbanco, Inc. | Robert H. Young | Sr. EVP / CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2021 | 2,000 | 2,000 | - | - | Stock Option | |
| Wesbanco, Inc. | Robert H. Young | Sr. EVP / CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.49 per share. | 15 May 2021 | 947 | 30,935 (0%) | 0% | 39.5 | 37,397 | Common Stock |
| Wesbanco, Inc. | Robert H. Young | Sr. EVP / CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.49 per share. | 15 May 2021 | 77 | 30,858 (0%) | 0% | 39.5 | 3,041 | Common Stock |
| Team, Inc. | Robert Young | President, AID | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 1,018 | 7,765 (0%) | 0% | 0 | Common Stock | |
| Team, Inc. | Robert Young | President, AID | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.00 per share. | 15 Mar 2021 | 302 | 7,463 (0%) | 0% | 0 | Common Stock | |
| Wesbanco, Inc. | Robert H. Young | Sr. EVP / CFO | Purchase of securities on an exchange or from another person at price $ 25.00 per share. | 04 Aug 2020 | 1,200 | 1,200 | - | 25 | 30,000 | Depositary Shares |
| Wesbanco, Inc. | Robert H. Young | Sr. EVP / CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2020 | 2,000 | 2,000 | - | - | Stock Option | |
| Wesbanco, Inc. | Robert H. Young | Sr. EVP / CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2020 | 438 | 31,242 (0%) | 0% | 0 | Common Stock | |
| Wesbanco, Inc. | Robert H. Young | Sr. EVP / CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 18.40 per share. | 19 May 2020 | 1,004 | 20,338 (0%) | 0% | 18.4 | 18,474 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges